Author: Ellen

If intervening ahead of symptoms in Alzheimer’s disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today, and his team at Washington University (WashU) – testing drugs provided […]

An experimental Alzheimer’s drug that had previously appeared to show promise in slowing the deterioration of thinking and memory has failed in a large Eli Lilly clinical trial, dealing a significant disappointment to patients hoping for a treatment that would alleviate their symptoms.

Nobody knew each other’s name. Even so, 60 people who either were at risk of having an autosomal-dominant Alzheimer’s mutation, or were accompanying someone who was, exchanged information about a shared problem. There were moments of validation—“Denial has divided my family, too!”—and apprehensive questions—“Do you want to know if you have it?”